Quince Therapeutics, Inc. (QNCX): R&D Expense
$35.38M
Year ended 2025-12-31
$32.99M
Trailing 12 months to 2026-06-30
+12.0%
3-year compound annual growth
-10.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.38M | +90.3% | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | $18.59M | +96.8% | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | $9.45M | -62.5% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $25.18M | -58.6% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $60.80M | -0.8% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $61.31M | +102.9% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $30.21M | +199.6% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $10.09M | n/a | 2021-03-01, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | $35.38M | +90.3% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $17.50M | -75.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $37.59M | -10.1% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $19.57M | +50.9% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
Compare QNCX, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗